» Articles » PMID: 27895695

The Effects of Guizhi Fuling Capsule Drug Serum on Uterine Leiomyoma Cells and Its Mechanism

Overview
Date 2016 Nov 30
PMID 27895695
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

To observe the effects of Guizhi Fuling Capsule (GZFLC) drug serum on uterine leiomyoma cells and explore its mechanism. . Sixty Sprague Dawley rats were randomly divided into two groups (normal saline lavage group and GZFLC lavage group), then, respectively, blank serum and GZFLC drug serum were collected, and finally human uterine leiomyoma cells were treated. Human leiomyoma tissues were collected from 20 patients who underwent uterine leiomyomas operations, and leiomyoma cells were primary cultured. The leiomyoma cells were treated by GZFLC drug serum in different concentrations (10%, 20%, and 30%) and variable treatment time (12 h, 24 h, 36 h, 48 h, and 72 h). Cell proliferation was observed using CCK8 assay. Flow cytometry and Annexin V/PI were used to assay the effects of GZFLC drug serum on cell apoptosis. Western blot analysis was used to assay the effects of GZFLC drug serum on TSC2, FOXO, and 14-3-3 expression in uterine leiomyoma cells. . In the concentrations of 10%30%, GZFLC drug serum could inhibit proliferation of leiomyoma cells in dose-dependent manner; at the time of 36 h, cell inhibition rate was at the peak; GZFLC drug serum could induce apoptosis of leiomyoma also in a dose-dependent manner, and apoptosis rate quickly achieved maximum at 12 h time points, and then second apoptosis peak appeared at 36 h. Compared to nontreatment group, TSC2, FOXO, and 14-3-3 expressions in drug serum group were significantly changed after 12 h treatment. . GZFLC drug serum can efficiently inhibit the proliferation and induce apoptosis of leiomyoma cells, which is related to the 14-3-3 pathway.

Citing Articles

Complementary Chinese Herbal Medicine Treatment is Associated with a Reduction of Surgical Rate in Patients with Dysfunctional Uterine Bleeding: A Propensity-Score Matched Cohort Study.

Lin Y, Lin W, Wu M, Lin C, Yang S, Yen H Int J Womens Health. 2024; 16:1361-1375.

PMID: 39157002 PMC: 11328855. DOI: 10.2147/IJWH.S461730.


Design, synthesis, molecular modeling, and bioactivity evaluation of 1,10-phenanthroline and prodigiosin (Ps) derivatives and their Copper(I) complexes against mTOR and HDAC enzymes as highly potent and effective new anticancer therapeutic drugs.

Cetin M, Peng W, Unruh D, Mayer M, Mechref Y, Yelekci K Front Pharmacol. 2022; 13:980479.

PMID: 36267272 PMC: 9578020. DOI: 10.3389/fphar.2022.980479.


Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review.

Arip M, Yap V, Rajagopal M, Selvaraja M, Dharmendra K, Chinnapan S Front Pharmacol. 2022; 13:878407.

PMID: 35800452 PMC: 9256340. DOI: 10.3389/fphar.2022.878407.


The Influence of Intraoperative Ultrasound Monitoring on the Risk of Recurrence and Reoperation in Patients with Hysteromyomectomy.

Yu S, Xiang Y Contrast Media Mol Imaging. 2022; 2022:4366840.

PMID: 35800231 PMC: 9203201. DOI: 10.1155/2022/4366840.


The Multiple Pharmacologic Functions and Mechanisms of Action of Guizhi Fuling Formulation.

Gao J, Yang J, Lu Z, Dong X, Xu Y Evid Based Complement Alternat Med. 2022; 2022:6813421.

PMID: 35529925 PMC: 9076289. DOI: 10.1155/2022/6813421.


References
1.
Yao Z, Shulan Z . Inhibition effect of Guizhi-Fuling-decoction on the invasion of human cervical cancer. J Ethnopharmacol. 2008; 120(1):25-35. DOI: 10.1016/j.jep.2008.07.044. View

2.
Wang S, Li X, Li Z, Lu J, Fang W, Ding Y . Gene expression profile changes and possible molecular subtypes in differentiated-type nonkeratinizing nasopharyngeal carcinoma. Int J Cancer. 2010; 128(4):753-62. DOI: 10.1002/ijc.25392. View

3.
Kovacs K, Lengyel F, Wilhelm F, Vertes Z, Sumegi B, Vertes M . Involvement of FKHR (FOXO1) transcription factor in human uterus leiomyoma growth. Fertil Steril. 2009; 94(4):1491-1495. DOI: 10.1016/j.fertnstert.2009.07.1670. View

4.
Du J, Liao W, Wang Y, Han C, Zhang Y . Inhibitory effect of 14-3-3 proteins on serum-induced proliferation of cardiac fibroblasts. Eur J Cell Biol. 2005; 84(10):843-52. DOI: 10.1016/j.ejcb.2005.06.006. View

5.
Wallach E, Vlahos N . Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004; 104(2):393-406. DOI: 10.1097/01.AOG.0000136079.62513.39. View